Alpenglow Biosciences and PathNet Form Strategic Partnership to Advance National Platform for 3D AI Cancer Diagnostics
We are announcing a new strategic partnership with PathNet to advance clinical-grade 3D AI diagnostics in urologic oncology.
The collaboration brings together PathNet’s national pathology network and outcomes-linked tissue archives with Alpenglow Biosciences’ clinical 3D pathology platform, including volumetric imaging and AI-powered spatial analytics.
Initial efforts focus on prostate and bladder cancer, with the goal of moving beyond the limits of 2D histology toward predictive, full-volume tissue insight that can scale in real clinical workflows.
This partnership marks an important step toward routine clinical adoption of 3D digital pathology in the United States.
“PathNet’s leadership in urologic oncology, digitization, and AI, along with its strong national footprint, makes it an exceptional partner as we bring clinical 3D pathology to market. Together, we are building diagnostic tools that deliver insights not achievable with conventional 2D histology.”
